Marker Therapeutics, Inc. Common Stock
MRKRMarker Therapeutics, Inc. is a biotechnology company focused on the development of targeted T-cell therapies for cancer. Utilizing its proprietary MultiVax platform, the company designs and manufactures personalized immunotherapies aimed at activating the patient's immune system to fight various cancers. Founded to advance innovative cancer treatment options, Marker Therapeutics aims to improve outcomes for patients with difficult-to-treat tumors.
Company News
Marker Therapeutics announced CEO Dr. Juan Vera will participate in a fireside chat at the H.C. Wainwright conference on September 10, 2025, discussing their Multi-Antigen Recognizing (MAR) T cell platform and recent clinical developments.
Marker Therapeutics reported promising results from its Phase 1 APOLLO study of MT-601, a multi-antigen T cell therapy for lymphoma. The study showed 66% objective response rates in Non-Hodgkin Lymphoma patients, with 50% achieving complete response and a favorable safety profile.
Marker Therapeutics and Cellipont Bioservices have announced a collaboration to advance the cGMP manufacturing of MT-601, Marker's multi-antigen recognizing T cell therapy for lymphoma patients. The collaboration aims to accelerate clinical supply and lay the foundation for a potential pivotal trial and commercial readiness.
Marker Therapeutics, a clinical-stage immuno-oncology company, announced that its President and CEO will present at the Citizens JMP Hematology and Oncology Summit on December 2, 2024. The presentation will provide an overview of the company's technology and clinical developments.
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study
